7 February 2022 - Azurity Pharmaceuticals today announced the U.S. FDA approval of Fleqsuvy (baclofen) 25 mg/5 mL concentrated suspension for the treatment of spasticity from multiple sclerosis or patients with spinal cord injuries and other spinal cord diseases.

Fleqsuvy is a grape flavoured oral suspension formulation of baclofen approved by the FDA for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.

Read Azurity Pharmaceuticals press release